Archive

Jugular Venous Compression via Soft Cervical Collar in Shunt-Refractory Low-Pressure Hydrocephalus: A Report of Two Cases

Third ventricular width decreased from 13 to 8 mm in case 1 and 13 to 4 mm in case 2; ventriculomegaly recurred on collar cessation and resolved on reapplication in case 1

Neurology · Cureus · 11 Sept

Beyond clinical endpoints: Rethinking ALS drug development through disease biology

If biology-driven endpoints replace survival and ALSFRS-R in ALS trials, the drugs you can offer patients may change faster than current approval standards allow.

Neurology · Fierce Biotech · 11 Sept

Neurosurgical Outcomes of Epilepsy Surgery Between 2017 and 2025: A Retrospective ESSQ-19 Study From a Tertiary Care Center

ESSQ-19 summary score was 84.1±21.7. Surgical complication domain scored 89.2±21.1 and seizure control 85.0±27.6, while psychosocial domain scored lower at 79.9±24.1.

Neurology · Cureus · 11 Sept

Preservation of Non-nidal Medial Veins During Microsurgical Resection of Cerebral Arteriovenous Malformations: Technical Considerations and Early Clinical Outcomes

Complete angiographic nidus eradication in all 16 patients, no perioperative mortality, and mRS 0-2 in 14 patients (87.5%). No delayed venous infarction or haemorrhagic transformation occurred.

Neurology · Cureus · 11 Sept

Joint impact of pathological burden and cognitive resilience on Alzheimer's disease risk.

Incident AD dementia: pathology hazard ratio 2.50 per s.d. (95% CI 2.30-2.72); resilience hazard ratio 0.51 per s.d. (95% CI 0.48-0.55). The two interacted multiplicatively.

Neurology · Nature Medicine · 11 Sept

Mass Effect Score Associations in Comatose Trauma Patients With Intracranial Hemorrhage Requiring Mechanical Ventilation: A Retrospective Study

Mortality and adverse outcomes were associated with MES ≥2 (both p 0.05). Failure to follow commands at three months was also associated with MES ≥2 (p 0.05).

Neurology · Cureus · 10 Sept

When Speech Signals Wilson Disease: A Case Report

Kayser-Fleischer rings, reduced serum ceruloplasmin, elevated 24-hour urinary copper, decompensated liver disease, and MRI signal changes in basal ganglia, thalami, and periventricular white matter confirmed Wilson disease; D-penicillamine and zinc led to clinical improvement

Neurology · Cureus · 10 Sept

Tumor-Related Trigeminal Neuralgia: Clinical Features, Pathophysiology, and the Contemporary Role of Radiosurgery in Tumor Control and Pain Relief

Microsurgery gave a higher proportion of favourable pain outcomes and, in one meta-analysis, longer median time to pain recurrence, with equivalent tumor control, mainly in petroclival and petrous apex meningioma.

Neurology · Cureus · 10 Sept

Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal

If you have patients on or awaiting BHV-7000 trials, recruitment is now paused pending rodent toxicity review, so discuss alternatives rather than enrolment timelines.

Neurology · Fierce Biotech · 10 Sept

Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial.

At 90 days, 69.7% on loberamisal reached mRS 0-1 versus 56.3% on placebo (risk difference 13.28%, 95% CI 7.24%-19.32%)

Neurology · JAMA · 10 Sept

Surgical Deconstruction of Recurrent Basilar Apex Aneurysms Refractory to Endovascular Treatment

Both patients achieved safe, immediate and durable aneurysm disconnection; angiographic posterior communicating artery presence and an intraoperative perforator-free zone were key to the approach

Neurology · Cureus · 9 Sept

Diagnostic Diplopia: Isolated Oculomotor Nerve Palsy With Normal Imaging

When imaging is normal in isolated oculomotor palsy, don't settle for microvascular cause—consider vasculitis, aneurysm, or infiltrative disease before discharging.

Neurology · Cureus · 9 Sept

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

MWT sleep latency rose 14.3-19.8 minutes with oveporexton versus -0.4 to -0.8 with placebo; ESS fell 9.7-11.8 versus 1.5-1.7; cataplexy fell 79.0-88.8% versus 27.7-39.1% (all P<0.001).

Neurology · NEJM · 9 Sept

Deepinder Goyal’s Temple Takes First Step Towards Validating Its Wearable

If validated, this wearable could offer non-invasive brain flow monitoring in clinics, aiding early detection of neurological conditions.

Neurology · Inc42 · 7 Sept

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

First therapy for Alexander disease—an ASO targeting GFAP—offers a disease-modifying option for a fatal leukodystrophy, though availability in India remains unclear.

Neurology · Fierce Biotech · 4 Sept

FDA Approves First Drug to Treat Alexander Disease

First-ever therapy for a fatal leukodystrophy; consider referral for pediatric or adult patients with confirmed GFAP mutation.

Neurology · FDA — Press Announcements · 4 Sept

Psilocybin proves promising in neuropathic pain mouse study

If confirmed in humans, psilocybin could offer a new option for chemotherapy-induced neuropathy, which often resists standard painkillers.

Neurology · Fierce Biotech · 3 Sept

Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.

Cumulative incidence of epilepsy increased from 9.5% (95% CI 7.8-11.3) at Alzheimer's diagnosis to 56.9% (51.7-61.7) after 9 years. Epilepsy associated with increased mortality (HR 2.10 [95% CI 1.57-2.82]; p<0.0001) and faster cognitive decline.

Neurology · Lancet · 3 Sept

Mechanical Thrombectomy in Ischemic Stroke With Medium or Distal Arterial Occlusion

For stroke patients with medium or distal occlusions, this trial clarifies whether adding thrombectomy to medical therapy improves outcomes—directly guiding your reperfusion decisions.

Neurology · JAMA · 1 Sept

Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion Research Summary

For stroke patients with medium or distal clots, this trial tests whether adding thrombectomy to standard care improves functional recovery—directly informing your reperfusion decisions.

Neurology · JAMA · 1 Sept

One-Year Outcomes After Endovascular Treatment for Large Acute Ischemic Stroke

Confirms thrombectomy benefit persists at 1 year for large-core strokes, supporting its use in patients you might otherwise manage medically.

Neurology · JAMA · 1 Sept

FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

For adults with narcolepsy type 1, this first full-spectrum oral option may reduce cataplexy and sleepiness, offering an alternative to stimulants and sodium oxybate.

Neurology · FDA — Press Announcements · 6 Aug

SOMNUM (SOMNUM) — Honeynaps Co., Ltd. (FDA K253390)

This AI-enabled neurology device gains US clearance; Indian clinicians should watch for local availability to aid neurological assessments.

Neurology · FDA — AI/ML-Enabled Medical Devices · 27 Jun

MeRT System — Wave Neuroscience (FDA K260402)

This clearance may expand access to MeRT for neurologists treating brain disorders, but clinical impact depends on evidence—check if it changes your protocol.

Neurology · FDA — AI/ML-Enabled Medical Devices · 3 Jun

myosmart. (13E522); myosmart.cuff (757M20-2); connectgrip. (560X27-1); myosmart trial kit (642V64=T) — Otto Bock Healthcare Products GmbH (FDA K253256)

For clinicians managing amputees, this cleared myoelectric system offers more intuitive prosthetic control, potentially improving functional outcomes and patient satisfaction in daily use.

Neurology · FDA — AI/ML-Enabled Medical Devices · 22 Apr

Stealth AXiS Cranial clinical application — Medtronic Navigation, Inc. (FDA K253379)

New FDA-cleared navigation software for cranial procedures—check if your centre adopts it to improve intraoperative accuracy and workflow.

Neurology · FDA — AI/ML-Enabled Medical Devices · 26 Mar

Onera SleepMap (SLEEPMAP) — Onera B.V. (FDA K253668)

FDA-cleared AI sleep monitor may offer home-based assessment, potentially reducing need for in-lab polysomnography in select patients.

Neurology · FDA — AI/ML-Enabled Medical Devices · 8 Mar

Mazor X System / Mazor X Stealth Edition — Mazor Robotics Ltd. (FDA K251316)

Spine surgeons can now use this cleared navigation platform to improve screw placement accuracy and reduce revision rates in complex procedures.

Neurology · FDA — AI/ML-Enabled Medical Devices · 11 Sept